BD4QoL has been accepted for Poster presentation (display) at the ESMO Congress 2022 which itook place in Paris from September 9th to 13th, 2022.

ESMO (European Society for Medical Oncology) is the leading professional organisation for medical oncology. With more than 25,000 members representing oncology professionals from over 160 countries worldwide, ESMO is the society of reference for oncology education and information.

ESMO’s core mission is to improve the quality of cancer care, from prevention and diagnosis all the way to palliative care and patient follow-up. It is to educate – doctors, cancer patients and the general public – on the best practices and latest advances in oncology.

The BD4QoL study is a multicenter, international, randomized (2:1), open-label, superiority trial. The primary endpoint is defined as a clinically meaningful global health-related quality at any point during 24 months post-treatment follow-up.

During the trial patients will be randomized to be followed up using the BD4QoL platform or per standard clinical practice. The BD4QoL platform includes a set of services to allow patients monitoring and empowerment through two main tools:

• the Point of Care dashboard, to manage all of the personal data and followup by clinical investigators
• a mobile application (mApp) installed on smartphones, that includes a chatbot for patients ecoaching.

Also, a web-form tool is provided to allow the QoL questionnaire completion.

You can find more information on the Congress on the event official page.